Company* |
Company* |
Type/Product Area | Terms/Details (Date) |
ActiveSight* |
Celgene Corp. (CELG) |
ActiveSight will provide structural biology services to Celgene subsidiary Signal Pharmaceuticals LLC |
Efforts will focus on co-crystallography of Celgene's small molecules with a human drug target protein from ActiveSight; ActiveSight gets an up-front fee and potential milestone payments (7/20) |
AEterna |
Spectrum Pharmaceuticals Inc. (SPPI) |
Spectrum gained rights to the LHRH antagonist D-63153 in all indications in North America and India |
AEterna gets an up-front payment in cash and equity, and is eligible to receive milestone and royalty payments; Spectrum gets a portion of any revenues related to development or sales in Japan; rights previously were held by Baxter International (8/12) |
Agensys Inc.* |
Genentech Inc. (NYSE:DNA) |
Genentech got exclusive worldwide rights to develop drugs and diagnostics based on two Agensys cancer targets; Genentech also licensed certain monoclonal antibodies from Agensys |
Successful development of antibodies to each target would trigger milestone payments that could exceed $90M; Agensys got an up-front payment and equity investment, and would get royalties on any sales; non-antibody development also would result in milestone and royalty payments; Agensys retained rights to vaccines and certain diagnostic products (7/22) |
Ambion Inc.* |
Benitec Ltd. (Australia; ASX:BLT) |
Companies settled U.S.-based patent-infringement litigation |
As part of the deal Ambion gained a nonexclusive worldwide license to make and sell DNA-directed RNAi-based products (10/10); Benitec settled litigation with GenScript on similar terms (8/24) |
Anadys |
Aphoenix Inc.* (Japan) |
Anadys will use its technologies to discover and advance lead compounds against Aphoenix targets in multiple indications |
Anadys gets up-front and research payments in the three-year deal, as well as potential milestone and royalty payments (9/9) |
Array |
QLT Inc. (Canada; QLTI) |
Drug discovery collaboration to create a series of small-molecule therapeutics against cancer targets identified by QLT |
Array gets research funding as well as potential milestone and royalty payments; further terms were not disclosed (8/10) |
Artemis |
Acceleron Pharma Inc.* |
Artemis will apply its ArteMice technology to generate a genetically engineered mouse model system for Acceleron |
Acceleron will use the mouse model to develop drugs for treating musculoskeletal and metabolic disorders; terms were not disclosed (8/26) |
Artemis |
Regeneron Pharmaceuticals Inc. (REGN) |
Regeneron got nonexclusive rights to use gene-switch technology based on ligand-regulated DNA recombination |
The sublicense covers internal research purposes only; terms of the deal were not disclosed (8/9) |
Artemis |
Evotec Neurosciences GmbH* (Germany) |
Artemis will apply its ArteMice technology to help Evotec generate genetically engineered mouse models |
Evotec will use the models to study genes thought to be involved in diseases of the central nervous system; terms were not disclosed (7/14) |
Artemis |
Biovitrum AB* (Sweden) |
Artemis will develop knock-down transgenic mice for use in Biovitrum research programs |
Terms of the services agreement were not disclosed (7/7) |
Atrix |
Arius Pharmaceuticals Inc.* |
Arius got a worldwide license to develop and market BEMA transmucosal drug delivery technology |
Atrix gets an up-front licensing fee and potential milestone payments, as well as reimbursement for R&D support; Atrix retains co-promotion rights to the BEMA fentanyl product (7/21) |
AutoGenomics |
Gentris Corp.* |
Deal to integrate Gentris' CYP450 diagnostic products onto the AutoGenomics' Infiniti platform |
They intend to introduce a series of panels in pharmacogenomic testing for detecting genetic mutations related to a patient's drug metabolism status (7/27) |
Axelar AB* |
Biovitrum AB* (Sweden) |
Biovitrum acquired a program that includes molecules that inhibit the IGF-1 receptor, which is involved in tumor cell growth |
Biovitrum will collaborate on the program with the Karolinska Institute in Sweden, which formed Axelar; Biovitrum also will get access to other chemical entities; terms of the deal were not disclosed (8/26) |
BioFocus plc |
NeuroTargets Ltd.* (UK) |
Each will contribute technology to discover compounds that bind to a target involved in nerve repair |
NeuroTargets is providing validation and screening and BioFocus discovery expertise in the deal; resulting candidates would be partnered; terms were not disclosed (8/11) |
BioTie |
Somaxon Inc.* |
Somaxon got an option to exclusively license North American rights to nalmefene for treating pathological gambling and other impulse-control disorders |
BioTie gets a $0.2M option fee and would get a $3M licensing fee and up to $10M in development milestones, as well as royalties on any sales; the license is contigent on a clinical development agreement with the FDA (7/20) |
BioWa Inc.* |
Biogen Idec Inc. (BIIB) |
Biogen licensed rights to use Potelligent technology for enhancing antibody-dependent cellular cytotoxicity |
BioWa gets a signing fee, and could receive milestone payments and royalties; Biogen has a right to gain exclusive commercial rights to develop antibodies for an undisclosed number of targets (6/30) |
Chiron Corp. |
InterMune Inc. (ITMN) |
InterMune got nonexclusive rights to develop and sell small-molecule agents against certain hepatitis C targets |
InterMune got rights to Chiron patents for use in development of protease inhibitors; terms were not disclosed (9/13) |
Cimab SA* (Cuba) and YM Biosciences Inc. (Canada; TSE:YM) |
CancerVax Corp. (CNVX) |
CancerVax got exclusive rights to three specific active immunotherapeutic candidates targeting the EGFR pathway for cancer in North America, Western Europe, Canada, Japan, Australia and New Zealand; the lead product, SAI-EGF, is in Phase II trials |
CancerVax will make access and technology payments of $6M over three years; CancerVax also would pay up to $35M in milestones upon approvals in the biggest markets; milestone and other payments would be made in U.S.-origin goods such as food or medicine, to be used for the food of the Cuban people (7/15) |
Crucell NV (the |
Vaxin Inc.* |
Vaxin gets rights to use Crucell's PER.C6 human cell line technology in recombinant adenoviral vaccines against certain respiratory viruses |
Crucell gets an undisclosed up-front payment and annual maintenance fees, as well as potential milestones and royalties (9/13) |
Crucell NV (the |
MorphoSys AG (Germany; FSE:MOR) |
MorphoSys gets rights to Crucell's PER.C6 human cell line technology for use in antibody research programs |
MorphoSys also got an option to a license for the clinical and commercial production of antibodies; Crucell and DSM get undisclosed up-front and annual payments (9/8) |
Crucell NV |
Syngernics LLC* and Synco Bio Partners Investments* (the Netherlands) |
Synergenics and Synco got rights to use the PER.C6 cell line for developing monoclonal antibodies for infectious diseases |
Crucell and DSM get an up-front payment and annual maintenance fees; further details were not disclosed (8/20) |
CyDex Inc.* |
TargeGen Inc.* |
TargeGen got rights to use Captisol formulation technology with TG 100-115, a kinase inhibitor being developed for acute myocardial infarction |
TargeGen also can use the technology for additional compounds developed in the next five years; terms of the deal were not disclosed (6/30) |
Cyprotex plc |
Peakdale Discovery Ltd.* (UK) |
Cyprotex will use its in silico Cloe Screen technology to evaluate the ADME properties of 8,500 compounds |
The data will be used to design new compounds; terms were not disclosed (7/1) |
Dyax Corp. |
Amgen Inc. |
Amgen got a nonexclusive license to antibody phage-display libraries for discovering human antibodies |
Dyax gets up-front and annual license fees, product license exercise fees, clinical milestone payments, and royalties on sales of any resulting products (7/29) |
diaDexus Inc.* |
Medarex Inc. |
They will develop antibodies to three cancer targets outside of lung cancer under an expansion of an existing collaboration |
They will share costs and any resulting profits; separately, Medarex licensed a target in ovarian cancer, for which it will pay diaDexus an up-front payment and potential milestones and royalties (9/16) |
Eiffel |
NanoMaterials Technology Pte. Ltd.* (Singapore) |
Deal to develop a hybrid technology for use in re-engineered drugs |
Eifell's Super Critical Fluids technology will be combined with NanoMaterial's High Gravity Controlled Precipitation technology under undisclosed terms (6/29) |
Enzon |
Pharmagene |
Deal to develop a long-acting formulation of Pharmagene's PGN0052, a synthetic version of human secretin in Phase IIa trials; it initially is being developed for cystic fibrosis |
Enzon will apply its PEGylation technology in an attempt to improve the properties of the product; Enzon gets an initial fee and a potential milestone payment; they could enter a deal to share equally in costs and profits, terms under which Pharmagene could get $47.5M in license and milestone payments; or a deal could entail Enzon getting certain co-marketing rights and royalties on worldwide sales (9/16) |
Evotec OAI AG |
Lectus |
Evotec will supply medicinal chemistry resources to support Lectus' discovery and development programs |
Terms were not disclosed; the work will focus on ion channel programs in urinary bladder disorders, angina and hypertension (8/2) |
Evotec OAI AG |
ActivBiotics Inc.* |
Deal to apply Evotec technology to a lead-optimization program at ActivBiotics in anti-infectives |
Evotec will use its new rational drug design platform, EVOrationale, in the deal, terms of which were not disclosed (7/29) |
Evotec OAI AG |
Morphochem |
Evotec will support development of a dual-action antibiotic at Morphochem |
Evotec's EVOdevelop chemical and development platform will be used in the effort; terms were not disclosed (7/21) |
eXegenics Inc. |
NLC Pharma |
eXegenics licensed to NLC its QCT drug discovery technology |
eXegenics could receive up to $20M from royalties, licenses or the sale of QCT technology to third parties (9/8) |
ExpressOn |
Auvation Ltd.* (UK) |
ExpressOn will apply its array technology to up to 20 target genes provided by Auvation, and design silencing reagents |
ExpressOn gets up-front payments and milestone payments on any silencing reagents selected for drug development (8/12) |
GenData |
Celera Diagnostics (venture of Celera Genomics Group and Applied Biosystems Group) |
GenData will provide DNA samples and clinical data to support discovery by Celera of genetic markers associated with an autoimmune disease |
Celera Diagnostics is doing the work on behalf of Celera Genomics; terms and specific details were not disclosed (9/15) |
GTx Inc. |
Tessera Inc.* |
Collaboration to develop a test to detect high-grade prostatic intraepithelial neoplasia |
GTx will provide clinical samples from its completed Phase IIb trial that evaluated Acapodene (toremifene citrate) in the condition; terms were not disclosed (7/27) |
Harvest |
Haemonetics Corp.* |
Harvest sold its blood conservation technologies to Haemonetics |
Haemonetics gains technologies that are synergistic to its own; terms of the deal were not disclosed (8/30) |
Hybridon Inc. |
Alnylam Pharmaceuticals Inc. (ALNY) |
Alnylam got an exclusive license to target vascular endothelial growth factor with RNAi molecules for ocular indications |
Hybridon received an up-front payment and is eligible for future milestone payments and royalties (8/3) |
Iconix |
ICOS Corp. |
Iconix will provide chemogenomic profiling and analysis technologies to ICOS |
ICOS will apply the platform to develop an understanding of preclinical drug responses; terms were not disclosed (6/24) |
Illumina Inc. |
Galileo Genomics Inc.* (Canada) |
Galileo purchased two Illumina genotyping systems to map candidate regions in at least five gene discovery programs |
Illumina also licensed the diagnostic rights to Galileo's osteoarthritis gene discovery program; the deal is worth more than $1.5M to Illumina (8/19) |
Illumina Inc. |
Genomas Inc.* |
Deal to design and validate gene marker panels that will have application in personalized medicine for obesity |
Genomas will use the Illumina BeadStation 500GX to discover markers for use in PhysioTypes, predictors incorporating haplotypes from various genes with other information; terms were not disclosed (7/20) |
Invitrogen |
Exelixis Inc. |
Invitrogen will provide Exelixis high- throughput screening assays for drug discovery in single live cells |
Exelixis will use the assays for lead discovery and optimization; terms of the deal were not disclosed (8/12) |
irsiCaixa* |
CombiMatrix Group (CMBX; unit of Acacia Research Corp.) |
Existing deal was expanded three years and will include two siRNA HIV candidates for preclinical development; irsiCaixa also will do virology work in hepatitis C |
CombiMatrix and potential partners will pursue preclinical development, with irsiCaixa providing research as appropriate; irsiCaixa gets research funding and potential milestone and royalty payments (7/20) |
Juvaris |
Cell Genesys Inc. (CEGE) |
Deal for preclinical evaluation of Juvaris' cationic lipid-DNA complexes with certain Cell Genesys product candidates |
Juvaris' immunostimulant platform will be used by Cell Genesys in tumor applications and test systems; terms were not disclosed (7/20) |
Medivir AB |
Biovitrum AB* (Sweden) |
Collaboration to develop a drug candidate for Type II diabetes |
They will use Medivir's protease expertise and Biovitrum's knowledge of metabolic diseases in the effort; terms of the deal were not disclosed (7/16) |
MethylGene |
EnVivo Pharmaceuticals Inc.* |
EnVivo exercised its option to license isotypic-selective small-molecule histone deacetylase inhibitors for treating neurodegenerative diseases |
MethylGene gets $1.1M in license and research payments, and a potential milestone payment based on early development; they will jointly fund development and would share any resulting profits (7/13) |
Millennium |
Portola Pharmaceuticals Inc.* |
Portola licensed a Factor Xa inhibitor program from Millennium, from which it was spun out in November 2003 |
Portola will make milestone and royalty payments to Millennium upon achievement of certain events, in exchange for the exclusive, worldwide license (8/5) |
Millennium |
Gene Logic |
Gene Logic acquired a technology program for preclinical and clinical drug development, focused on identifying the best indications for drugs, along with an associated six- person research team |
Gene Logic is paying $3.5M in cash or stock, $1M to the researchers and granting Millennium a three-year license to its toxicology database; the first project is Millennium's MLN4760, formerly studied for obesity, for which Gene Logic could receive various payments and sales royalties; Gene Logic also acquired Millennium's MC-4 antagonist program (7/23) |
Mirus Bio |
Genzyme Corp. |
Genzyme got nonexclusive rights to use Mirus' technologies in its research programs |
The deal includes Mirus' hydrodynamic gene- delivery technology; terms were not disclosed (9/8) |
Mologen AG |
Starvax Inc.* |
Starvax licensed the dSLIM-based DNABarrier II product in China and elsewhere in Asia |
Mologen gets €1M up front and potential milestone and royalty payments; Mologen will invest €0.8M in the clinical development program in China (7/12) |
Morphotek Inc.* |
Protein Design Labs Inc. (PDLI) |
PDL gets access to Morphodoma and Suppressor of Immunoglobulin Production technology, and Morphotek gets access to technology for antibody humanization |
Morphotek has an option to move from a research to commercial license on humanized antibodies; PDL has options to exercise commercial licenses for antibodies in all therapeutic areas; terms of the deal were not disclosed (7/19) |
M's Science |
AGY Therapeutics Inc.* |
AGY got exclusive rights to a sigma receptor agonist, AGY-94806 (SA4503), which AGY initially plans to study in stroke recovery |
AGY intends to take the compound into Phase II trials in stroke recovery by early in 2005; AGY also got rights in traumatic brain injury and spinal cord injury, as well as rights to license additional CNS indications; terms were not disclosed (7/20) |
Nautilus |
Creabilis Therapeutics Srl* (Italy) |
Collaboration to develop an improved variant of CT500, an anti- MGB1 variant protein |
Nautilus' technology will be used to improve the pharmacodynamic profile of the product; terms were not disclosed (9/3) |
NeoGenesis |
Achaogen* |
NeoGenesis will apply its technologies to the discovery of drug candidates against selected targets |
Terms and details of the collaboration were not disclosed (8/26) |
NeuroSearch |
TopoTarget |
Deal to develop NeuroSearch's Endovion (NS3728), a chloride channel blocker for treating cancer |
TopoTarget will fund all future development and the companies will share any revenues under undisclosed terms (8/12) |
Novosom AG* |
Nucleonics Inc.* |
Deal to apply Novosom's Smarticles formulation technology to the delivery of Nucleonics' expressed RNA interference-based therapeutics |
Terms of the deal involving Novosom's liposomal formulations were not disclosed (8/17) |
OctoPlus |
SurModics Inc. |
SurModics got an option to exclusively license two classes of biodegradable polymers |
The polymers would be used in delivering drugs from medical devices; terms were not disclosed (6/29) |
Orexo AB* |
Endo Pharmaceuticals Inc. (ENDP) |
Endo got exclusive rights in North America to Orexo's sublingual mucoadhesive fentanyl product, Rapinyl |
Orexo gets $10M up front and up to $22M in milestone and other payments through FDA approval; Orexo also would receive double-digit royalties and potential sales milestone payments (8/18) |
OriGene |
Xantos Biomedicine AG* (Germany) |
Xantos acquired access to the TrueClone Collection of full-length human cDNA clones |
Xantos uses the clones to identify and functionally validate novel targets; terms were not disclosed (8/9) |
Oxford |
Viragen Inc. (AMEX:VRA) |
Viragen gets worldwide exclusive rights to use LentiVector technology in its collaboration with the Roslin Institute |
Viragen and Roslin are developing avian transgenic technology; Oxford gets an up-front license fee and annual maintenance payments, as well as potential milestones and royalties (7/6) |
Phares |
Inyx Inc. |
Signed letter of intent under which Inyx would acquire technology for developing inhalation therapy drugs delivered in aerosol formats |
The deal was expected to be completed 60 days after signing; terms were not disclosed; the technology uses a lipid-binding matrix for delivering incompatible or unstable drug substances to mucosal membranes (7/22) |
Phenomenome |
Biomira Inc. |
Phenomenome will perform metabolome analysis to discover markers for efficacy of cancer treatments |
Details on the deal were not disclosed (7/12) |
Phenomix |
Genentech |
Genentech gets access to forward genetics technology to identify targets fortreating immune disorders |
Phenomix gets an up-front payment and an equity investment, and also will get research funding and potential milestone payments; Phenomix retains rights to develop products based on certain targets (7/12) |
PPL |
Pharming Group NV (the Netherlands; Euronext:PHARM) |
Pharming acquired the patent portfolio of PPL, which is selling its assets |
The IP includes patents on recombinant human fibrinogen and recombinant tissue sealant compositions, as well as for production of recombinant proteins; terms were not disclosed (8/23) |
Protalix |
Icon Genetics AG* (Germany) |
Two-year deal to develop plant cell lines as a platform for expressing recombinant proteins |
Icon's amplification technologies will be used with Protalix expression systems based on plant cell cultures; terms were not disclosed (6/22) |
Provalis plc |
Chiron Corp. (CHIR) |
Chiron got a 12-month option to evaluate Provalis' protein-based vaccine to prevent Group B Streptococcus infection |
Chiron Vaccines paid an option fee and has the right to exclusively license or acquire the vaccine candidates, in exchange for milestone and royalty payments (7/1) |
RESprotect |
Australian Cancer Technology Ltd. (Australia; ASX:ACU) |
ACT acquired North American rights to develop RP101, a Phase I/II product being developed for pancreatic cancer |
As part of the deal ACT will acquire 10% of RESprotect; further terms were not disclosed (9/10) |
Roboscreen |
Prion AG* (Switzerland) |
Roboscreen licensed its prion protein-specific monoclonal antibody to Prionics |
Prionics will use the antibody in diagnostic tests; terms were not disclosed (8/18) |
Seattle Genetics |
Celera Genomics Group (NYSE:CRA) |
Collaboration to jointly discover and develop antibody-based therapies for cancer |
Seattle Genetics will screen cell-surface proteins discovered at Celera as antigen targets; they will co-fund development and would share any resulting profits; either party may opt out of a particular product in exchange for royalties; Seattle Genetics also could earn milestones for any co-developed antibody-drug conjugates (7/21) |
Shamrock |
Intra-Cellular Therapies Inc.* |
Shamrock will provide integrated structural proteomics services for an ICT protein target |
Shamrock gets an up-front fee and potential milestone payments; additional terms were not disclosed (8/5) |
Sunesis |
Biogen Idec Inc.(BIIB) |
Collaboration to discover and develop small-molecule cancer drugs targeting kinases; they will use Sunesis' Tethering technology in the effort |
Sunesis gets a $7M technology access fee and $14M equity investment up front, as well as research funding over four years, along with potential milestone and royalty payments; Sunesis retains co-development and co-promotion options (9/7) |
SuperGen |
MGI Pharma Inc. (MOGN) |
MGI gained exclusive worldwide rights to Dacogen (decitabine), a drug being developed for myelodysplastic syndromes |
MGI is purchasing $40M of SuperGen stock at $10 per share and paying up to $45M in regulatory and commercial milestones; MGI also will pay at least $15M to support further development and would pay sales royalties of 20% to 30% (9/1) |
Supratek |
Tapestry Pharmaceuticals Inc. (TPPH) |
Supratek will apply its Biotransport formulation technology to Tapestry compounds |
Supratek can get milestone and royalty payments in the deal; Tapestry will fund development and would commercialize any resulting products (7/22) |
The Immune |
NovaRx Corp.* |
NovaRx got rights to cancer cell line vaccines that IMNR had licensed from the Sidney Kimmel Cancer Center |
NovaRx is paying $1.05M for the rights; it previously licensed other Sidney Kimmel technology from IMNR, for which IMNR has received milestone payments (9/8) |
Tranzyme Pharma Inc.* |
Gentris Corp.* |
Deal to develop cell lines for diagnostic assays to evaluate responses to drug treatment |
Gentris will provide genetic sequences on alleles involved in metabolism and Tranzyme will create human cell lines; they will jointly own resulting cell lines (6/24) |
Trine Pharmaceuticals Inc.* |
Mpex Pharmaceuticals Inc.* |
Mpex got exclusive rights to Trine's intellectual property in the field of bacterial efflux pump inhibitors |
Terms of the deal were not disclosed; Trine is the successor company to Microcide Pharmaceuticals Inc. (8/9) |
Valentis Inc. |
Genzyme Corp. |
Expanded deal giving Genzyme increased use of Valentis' GeneSwitch technology |
In return, Valentis gets certain rights to Genzyme's static mixer technology for use in plasmid DNA manufacturing (9/7) |
Vernalis plc |
Endo Pharmaceuticals Inc. (ENDP) |
Endo got exclusive rights to market Vernalis' approved migraine product Frova (frovatriptan) in North America |
Vernalis gets $30M up front, $15M payments for each of the first two years, and would get $40M upon approval in menstrually associated migraine; Vernalis also gets sales milestones of up to $255 if all targets are achieved; it also will get royalties on sales (7/14) |
Vernalis plc |
Biogen Idec Inc. (BIIB) |
Deal to advance Vernalis' adenosine A2A receptor antagonist program, which targets Parkinson's disease and other CNS disorders |
Vernalis gets a $10M license fee and a $6M investment from Biogen Idec, which gains exclusive worldwide rights to Vernalis' lead compound, V2006, and a backup compound; its also has option rights to the program; the deal value could reach $100M, excluding royalties, for Vernalis, which also has a U.S. co-promotion option (6/24) |
ViroPharma Inc. (VPHM) |
SIGA Technologies Inc. (SIGA) |
SIGA purchased early stage biodefense assets, including IP on developing drugs for smallpox and hemorrhagic fever viruses |
ViroPharma received $1M in cash and 1M SIGA shares, which were worth $1.48M at the time of the deal (8/25) |
Viventia Biotech Inc. (Canada; TSE:VBI) |
Acceptys Inc.* |
Acceptys got an exclusive right to evaluate a Viventia collection of fully human cancer antibodies |
Viventia gets an up-front payment, acquisition fees and potential milestone and royalty payments on any sales of antibodies that Acceptys licenses and develops (8/18) |
ZymoGenetics |
Serono SA (Switzerland; NYSE:SRA) |
Broad collaboration to research, develop and sell protein and antibody drugs based on discoveries by ZymoGenetics |
Serono is paying $20M for rights to license an unlimited number of proteins over five years, and buying $50M of ZymoGenetics stock; it also can license 12 ZymoGenetics programs over five years, and it licensed rights to fibroblast growth factor 18 and the IL-22 receptor; they will co-develop interleukin-31; ZymoGenetics gets $11.25M up front from those licenses, and could get license fees and milestones from all products selected by Serono, as well as royalties or profit sharing on any sales (9/8) |
Notes: | |||
* Private companies are indicated with an asterisk. | |||
# Item occurred before April 20 but was not included in the previous chart. | |||
Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market. | |||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; HSE = Helsinki Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange. | |||
